Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference58 articles.
1. Jacquillat C, Weil M, Gemon MF, et al.: Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). Cancer Res 1973, 33:3278–3284.
2. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69–79.
3. Sandlund JT, Harrison PL, Rivera G, et al.: Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002, 100:43–47.
4. Campana D: Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol 2008, 143:481–489.
5. Szczepanski T, Orfao A, van der Velden VH, et al.: Minimal residual disease in leukaemia patients. Lancet Oncol 2001, 2:409–417.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献